Isryl-M1 Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, formulated as a sustained-release tablet to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in enhanced glucose uptake and utilization. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with Metformin. Isryl-M1 is indicated for patients inadequately controlled on diet and exercise alone or those who have shown insufficient response to monotherapy with either agent. It is essential to initiate therapy under medical supervision, with dose adjustments based on glycemic response and tolerability. Contraindications include severe renal or hepatic impairment, metabolic acidosis, and conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia and lactic acidosis is recommended. Isryl-M1 Tablet SR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and lifestyle modifications.